NeoGenesis Capital
◆ Fund Size
$33.1M
◆ Location
United States
◆ Portfolio
3 companies
◆ Activity
Statusactively investing
◆ Links
◆ Share this fund
◆ Investment Thesis
NeoGenesis Capital applies a concentrated, single-ecosystem architecture to programmable biology. The thesis holds that the highest-returning ventures of the last decade were incubated inside closed ecosystems where access—not discovery—was the edge. Just as Anthropic, xAI, OpenAI, and SpaceX were produced by concentrated access to generational founders' ecosystems, NeoGenesis Capital is designed to invest in the engine Ben Lamm and George Church built—one that reads, writes, edits, and scales living systems—and in every company it produces. The concentration is the thesis.
◆ About NeoGenesis Capital
A venture fund focused on programmable biology at the intersection of synthetic biology and superintelligence, investing in companies addressing longevity, fertility, agriculture, environmental remediation, and AI-native genetic design.
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Team
| Name | Title | Role | Links |
|---|---|---|---|
| Ben Lamm | Co-Founder and CEO, Colossal Biosciences | Platform Architect (External) | |
| George Church, PhD | Co-Founder and Scientific Advisor, Colossal Biosciences | Platform Architect (External) | |
| Oliver Trevena | Head of Culture | Head of Culture | |
| Peter H. Diamandis, MD | Co-Founder and Partner | Partner | in𝕏 |
| Yianni Psaltis, PhD | Co-Founder and Managing Partner | Managing Partner | in𝕏 |
◆ Notable Investments
◆ FAQ
What does NeoGenesis Capital invest in?
NeoGenesis Capital invests in Biotech and AI Frontier Models at the pre-seed, seed, series-a and series-b stages.
Which geographies does NeoGenesis Capital focus on?
NeoGenesis Capital focuses on United States, and is headquartered in United States.